Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | TEK | Q02763 | 2/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.34 |
| ▸ | XPO1 | O14980 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20083188 | 0.94 | PDE4B (0.39) | PDE4BHDAC1HDAC6HCRTR1HCRTR2 | |
| SCHEMBL16113543 | 0.92 | PDE4B (0.41) | PDE4BHDAC1HDAC6HCRTR1HCRTR2 | |
| SCHEMBL16044615 | 0.92 | PDE4B (0.41) | PDE4BHDAC1HDAC6HCRTR1HCRTR2 | |
| SCHEMBL16047044 | 0.92 | PDE4B (0.39) | PDE4BHDAC1HDAC6HCRTR1HCRTR2 | |
| SCHEMBL16043829 | 0.91 | PDE4B (0.40) | PDE4BHDAC1HDAC6HCRTR1HCRTR2 | |
| SCHEMBL16044161 | 0.89 | PDE4B (0.41) | PDE4BHDAC1HDAC6HCRTR1HCRTR2 | |
| SCHEMBL16075840 | 0.89 | HDAC1 (0.41) | PDE4BHDAC1HDAC6CYP19A1USP7 | |
| SCHEMBL16113238 | 0.89 | CYP19A1 (0.39) | PDE4BHDAC1HDAC6HCRTR1HCRTR2 | |
| SCHEMBL16044021 | 0.89 | PDE4B (0.39) | PDE4BHDAC1HDAC6HCRTR1HCRTR2 | |
| SCHEMBL16075847 | 0.87 | FNTA (0.36) | PDE4BHDAC1HDAC6PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345902-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-10-30 | — | — | EP | disclosed |
| EP-2970212-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-04-25 | — | — | EP | disclosed |
| US-9040692-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-05-26 | — | — | US | disclosed |
| US-20140275531-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275531-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885HDAC1 623/4885HDAC6 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.